Lung Cancer Treatments
Protocol: STUDY00005566
Full Title
A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetael to Dostarlimab + Docetael to Docetael Alone In Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (COSTAR Lung)
Description
This research study is being done to test combinations of study drugs to treat lung cancer and see if they work better than the single drug docetaxel. Two of the drugs in this study (dostarlimab and cobolimab) are experimental which means they have not been fully tested yet and are not yet approved to treat any disease. The other drug in this study, docetaxel, is already approved by the United States Food and Drug Administration (FDA) and is a common treatment for patients with lung cancer.
Compensation: No
Eligibility
-Advanced or metastatic NSCLC, including squamous or non-squamous cell carcinoma.

-Received no more than 2 prior lines of therapy, which must include a platinum based chemotherapy (e.g., cisplatin, carboplatin) and an anti-PD-(L)1 antibody.

-Participant has measurable disease.

-Documented radiographic disease progression on prior platinum based chemotherapy and on or after prior anti-PD-(L)1 therapy.
Age Group: Adults
Principal Investigator: Zhen Wang
ClinicalTrials.gov: Open Study
Contact(s)
Kyle Pasquariello
kylepasq@buffalo.edu
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.